Microfluidics‐enabled Serial Assembly of Lipid‐siRNA‐sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy
Advanced Materials · 2023
DOI: 10.1002/adma.202209672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2023. Verfasst von Yao Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engin…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Nanoparticles. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Key R&D Program of China, Shenzhen Key Laboratory of Smart Healthcare Engineering, National Natural Science Foundation of China.
Abstract (Originalsprache)
Multi‐component nanoparticles (mNPs) hold great potential for disease prevention and treatment. However, a major barrier is the lack of versatile platforms to accommodate steps of assembly processes of mNPs. Here the microfluidics‐enabled serial assembly (MESA) of mNPs is presented. The microfluidic chip, as a mini‐conveyor of initial materials, sequentially enables the assembly of sorafenib supramolecule, electrostatic adsorption of siRNA, and surface assembly of protective lipids. The produced lipid‐siRNA‐sorafenib nanoparticles (LSS NPs) have ultrahigh encapsulation efficiencies for sorafenib (≈100%) and siRNA (≈95%), which benefit from the accommodation of both fast and slow processes on the chip. Although carrying negative charges, LSS NPs enable cytosolic delivery of agents and high gene silencing efficiency within tumor cells. In vivo, the LSS NPs delivering hypoxia‐induced factor (HIF1α)‐targeted siRNA efficiently regress tumors of Hep3B xenograft and hepatocellular carcinoma patient‐derived primary cells xenograft (PDCX) and finally extend the average survival of PDCX mice to 68 days. Thus, this strategy is promising as a sorafenib/siRNA combination therapy, and MESA can be a universal platform for fabricating complex nanosystems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guang…
- Division of Liver Surgery and Organ Transplantation Center, Shenzhen Third People's Hospital, Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, 518112, P.R. China.
ORCID-Profile: Xingyu Jiang
Förderung
- National Key R&D Program of China
- Shenzhen Key Laboratory of Smart Healthcare Engineering
- National Natural Science Foundation of China
- Guangdong Provincial Key Laboratory of Advanced Biomaterials
- Guangdong Innovative and Entrepreneurial Research Team Program
- Shenzhen Bay Laboratory
- Tencent Foundation through the XPLORER PRIZE
Zitieren
APA
Chen, Y., Zhao, D., Xiao, F., Li, X., Li, J., Su, Z., & Jiang, X. (2023). Microfluidics‐enabled Serial Assembly of Lipid‐siRNA‐sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. Advanced Materials. https://doi.org/10.1002/adma.202209672
Vancouver
Chen Y, Zhao D, Xiao F, Li X, Li J, Su Z, et al. Microfluidics‐enabled Serial Assembly of Lipid‐siRNA‐sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. Advanced Materials. 2023. doi:10.1002/adma.202209672
BibTeX
@article{Chen2023,
author = {Chen, Yao and Zhao, Dong and Xiao, Feng and Li, Xuanyu and Li, Jia'an and Su, Zhenwei and Jiang, Xingyu},
title = {Microfluidics‐enabled Serial Assembly of Lipid‐siRNA‐sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy},
journal = {Advanced Materials},
year = {2023},
doi = {10.1002/adma.202209672}
}
EUVIMED